Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced that enrollment in its Phase 3 APPROACH clinical trial has surpassed 86% and remains on track. The trial is evaluating HLP003, the company's lead proprietary novel serotonergic agonist, as an adjunctive treatment for major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to address a significant unmet medical need.
The APPROACH study is a key component of Helus Pharma's broader Phase 3 PARADIGM program, which also includes the EMBRACE study and the EXTEND long-term extension study. The company stated that this enrollment milestone supports its goal of reporting topline data from APPROACH in the fourth quarter of 2026, as it advances HLP003 toward potential commercialization.
Major depressive disorder affects millions worldwide, and current treatments often have limited efficacy or significant side effects. HLP003, as a novel serotonergic agonist, is designed to activate serotonin pathways believed to promote neuroplasticity, offering a new approach that could provide durable improvements in mental health. The FDA's Breakthrough Therapy Designation highlights the potential for HLP003 to offer a significant improvement over existing therapies, expediting its development and review process.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs) for mental health conditions. Beyond HLP003 for major depressive disorder, the company is developing HLP004 for generalized anxiety disorder, currently in Phase 2 trials, and has an extensive research portfolio of investigational NSAs.
The successful enrollment progress in the APPROACH trial is a positive indicator for the company's development timeline and brings hope to patients and healthcare providers seeking more effective treatments. For the industry, this advancement reinforces the potential of serotonergic agonists as a new class of therapeutics for mental health disorders, potentially reshaping treatment paradigms.
Investors and stakeholders can find more information and updates on Helus Pharma through the company's newsroom at https://ibn.fm/HELP and the full press release at https://ibn.fm/Qpikw. The company operates in Canada, the United States, the United Kingdom, and Ireland, with its website at www.helus.com.
As Helus Pharma continues to advance HLP003 through clinical development, the progress of the APPROACH trial will be closely watched by the medical community, investors, and patients alike. The topline data expected in late 2026 will be a critical milestone in determining the drug's efficacy and safety, potentially paving the way for a new treatment option for major depressive disorder.
